Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and prostate cancer in 2024Prioritizes development of CAN-3110 in recurrent high-grade glioma and initiation of investigational new drug (IND)-enabling studies in second indicationPlans to broaden discovery partnership opportunities based on the enLIGHTEN™ Discovery PlatformExtends cash runway into the fourth quarter of 2024 NEEDHAM, Mass., Nov.

将劳动力减少约50%，并减少商业制造费用，以优先考虑CAN-2409在非小细胞肺癌，胰腺癌，2024年前列腺癌优先发展CAN-3110在复发性高级别胶质瘤中的应用，并启动研究性新药（IND）-在第二项指标中开展研究-在启发的基础上扩大发现伙伴关系的机会™ Discovery PlatformExtended cash跑道进入2024年第四季度NEEDHAM，Mass。，Nov。

28, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced a strategic restructuring to focus on continuation and expansion of development of CAN-3110 as well as the enLIGHTEN™ Discovery Platform, while reducing the Company’s workforce and expenses associated with enabling commercial readiness of CAN-2409.

282023（GLOBE NEWSWIRE）-坎德尔治疗公司（坎德尔或该公司）（纳斯达克股票代码：CADL），一家专注于开发多模式生物免疫疗法以帮助患者对抗癌症的临床阶段生物制药公司，今天宣布进行战略重组专注于继续和扩大CAN-3110的开发以及开明™发现平台，同时减少公司的劳动力和与CAN-2409的商业准备相关的费用。

The Company expects to present initial activity and biomarker data for repeated injections of CAN-3110 in recurrent high-grade glioma in the second half of 2024 and new data for the second drug candidate based on the enLIGHTEN™ Discovery Platform in Q3 2024. The Company plans to continue to collect clinical data for key readouts for CAN-2409 in non-small cell lung cancer (NSCLC), with topline overall survival data of the open label phase 2 clinical trial expected in Q2 2024; pancreatic cancer, with an update on overall survival based on an interim analysis of the randomized, open label clinical trial in Q2 2024; and prostate cancer, with topline data for both fully enrolled randomized, blinded, placebo-controlled phase 2 and phase 3 clin.

该公司预计将于2024年下半年在复发性高级别胶质瘤中重复注射CAN-3110的初始活性和生物标志物数据，以及基于启发的第二种候选药物的新数据™发现平台在Q3 2024。该公司计划继续收集非小细胞肺癌（NSCLC）CAN-2409关键读数的临床数据，预计在2024年第二季度开放标签2期临床试验的总体生存数据；胰腺癌，根据2024年第二季度随机，开放标签临床试验的中期分析更新总生存期；和前列腺癌，具有完全登记的随机，盲法，安慰剂对照的2期和3期临床的顶线数据。